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The Framingham Heart Study has contributed importantlyto understanding of the causes of coronary heart disease
(CHD), stroke, and other cardiovascular diseases. Framing-
ham research has helped define the quantitative and additive
nature of these causes or, as they are now called, “cardiovas-
cular risk factors.”1 The National Cholesterol Education
Program (NCEP)2,3 has made extensive use of Framingham
data in developing its strategy for preventing CHD by
controlling high cholesterol levels. The NCEP guidelines2,3
adjust the intensity of cholesterol-lowering therapy with
absolute risk as determined by summation of risk factors. The
National High Blood Pressure Education Program (NHBPEP)
has set forth a parallel approach for blood pressure control. In
contrast to the NCEP,2 however, earlier NHBPEP reports
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issued through the Joint National Committee4 did not match
the intensity of therapy to absolute risk for CHD. “Normal-
ization” of blood pressure is the essential goal of therapy
regardless of risk status. Blood pressure–lowering therapy is
carried out as much for prevention of stroke and other
cardiovascular complications as for reduction of CHD risk.
Nonetheless, risk assessment could be important for making
decisions about type and intensity of therapy for hyperten-
sion. Thus, the most recent Joint National Committee report5
gives more attention to risk stratification for adjustment of
therapy for hypertension. Although Framingham data have
already been influential in the development of national
guidelines for risk factor management, the opportunity may
exist for both cholesterol and blood pressure programs to
draw more extensively from Framingham results when for-
mulating improved risk assessment guidelines and recom-
mending more specific strategies for risk factor modification.
The American Heart Association has previously used
Framingham risk factor data to prepare charts for estimating
CHD risk. Framingham investigators of the National Heart,
Lung, and Blood Institute prepared the original charts and
have now revised them using updated Framingham data.6 The
risk factors have been reclassified to be more consistent with
NCEP2,3 and Joint National Committee4,5 cut points. This
statement discusses the new Framingham charts, their essen-
tial features, and their appropriate use. In addition, several
issues related to CHD prevention raised by these charts are
examined. Other issues of risk management not considered in
these charts are also addressed.
Concept of Risk Factors
The concept of risk factors constitutes a major advance for
developing strategies for preventing CHD. The Framingham
Heart Study played a vital role in defining the contribution of
risk factors to CHD occurrence in the general population of
the United States. The major risk factors studied extensively
at Framingham include cigarette smoking,7–19 hyperten-
sion,11,20–33 high serum cholesterol and various cholesterol
fractions,34–50 low levels of high-density lipoprotein (HDL)
cholesterol,51–57 and diabetes mellitus.58–70 Advancing age is
also included as a risk factor in the Framingham charts
because of increased absolute risk with aging.71–75
Factors other than those listed as major risk factors increase
the likelihood for developing CHD. Among these, which have
been studied at Framingham or elsewhere, are obesity, physical
inactivity, family history of premature CHD, hypertriglyceride-
mia, small low-density lipoprotein (LDL) particles, increased
lipoprotein (a) (Lp[a]), increased serum homocysteine, and
abnormalities in several coagulation factors. Despite the poten-
tial importance of these other factors, they are not included in the
Framingham risk charts for both theoretical and practical rea-
sons. Nonetheless, they deserve some comment and consider-
ation of reasons for omission.
Framingham research reveals that both obesity76–78 and
physical inactivity79–82 are positively associated with risk for
CHD. Even so, Framingham data suggest that obesity and
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physical inactivity exert much of their adverse influence on
development of CHD through the major risk factors. Cer-
tainly it is possible that some of the increased risk imparted
by obesity and physical inactivity results from mechanisms
unrelated to the major risk factors. However, these mecha-
nisms are not well understood, and it is difficult to define the
risk imparted by these 2 factors independent of their influence
on the major risk factors. The NCEP2,3 and the AHA83 take the
position that obesity and physical inactivity are important
risk factors for CHD; however, they generally are not used in
quantitative risk assessment but rather stand as targets for
modification for everyone. Certainly both public health and
clinical efforts to promote desirable body weight and regular
exercise deserve a high priority in prevention.
Family history undoubtedly gives useful information about
an individual’s risk status. The NCEP2,3 considers a positive
family history of premature CHD a risk factor and uses it in
defining risk status. Framingham data also indicate that a
positive family history is a risk correlate.84 However, the
independent effect of a positive family history is difficult to
determine. Almost certainly familial influences on risk status
are mediated in part through blood pressure and serum
lipoprotein levels. Even so, a positive family history of
premature CHD cannot be ignored in clinical evaluation. Not
only should such a history increase awareness that an indi-
vidual is at greater risk, but it calls for evaluation of other
family members who may carry heritable risk factors.
Framingham risk scores do not include serum triglyceride
levels. Much research confirms that elevated serum triglyc-
erides are significantly correlated with risk.85 However, a
controversy has raged for many years over whether elevated
triglycerides are an independent risk factor.86 For example,
triglyceride levels are inversely correlated with serum HDL-
cholesterol levels.87 Moreover, in multivariate analysis of the
type used by Framingham investigators, low HDL-cholesterol
levels are a more consistent and reliable predictor of in-
creased CHD rates than are elevated triglyceride concentra-
tions.51–57 Thus, for simplicity, serum HDL-cholesterol levels
are used in Framingham scores6 and triglyceride levels are
ignored. This approach does not necessarily mean that tri-
glyceride-rich lipoproteins are not atherogenic. There is
growing evidence that certain species of these lipoproteins
are in fact atherogenic88,89 and probably should be targets of
therapy. Even so, for risk assessment, HDL-cholesterol levels
reflect a significant portion of the risk imparted by higher
serum-triglyceride concentrations. Another lipoprotein abnor-
mality, small LDL particles, is likewise strongly associated
with low serum HDL-cholesterol levels.90 Small LDL parti-
cles may promote atherosclerosis,91,92 but Framingham pre-
diction scores subsume them under the HDL category. Future
research will be required to define the independent contribu-
tions of the 3 components of the atherogenic lipoprotein
phenotype— elevated triglyceride-rich lipoproteins, small
LDL particles, and reduced HDL cholesterol—to overall
CHD risk.93 Use of serum HDL-cholesterol levels to define
the risk accompanying this complex phenotype is undoubt-
edly an oversimplification, but this drawback is partially
offset by clinical usefulness.
Lp(a) may be still another lipid risk factor. Several re-
ports94–97 indicate that elevated serum Lp(a) concentrations
are associated with high risk for CHD. Although other
reports98,99 fail to document a significant link between Lp(a)
levels and CHD rates, the preponderance of the evidence
seems to support a significant relationship. However, before
measurements of Lp(a) levels can be routinely used in risk
prediction, a stronger link between Lp(a) and atherogenesis
must be established, and accurate and inexpensive measure-
ments must be widely available.
Another category of candidate risk factors includes abnor-
malities in several coagulation factors.100 Among these factors
are platelet hyperreactivity,101 high levels of hemostatic pro-
teins (fibrinogen102–107 and factor IV108–111), defective fibrino-
lysis,112–115 and hyperviscosity of the blood.103 The most
extensive epidemiological data link plasma fibrinogen con-
centrations to CHD risk,102–107 but other abnormalities may be
important as well. In addition, evidence suggests that plasma
markers for endothelial cell injury and inflammation may be
predictors of acute coronary events.100 Research on these
various factors promises to provide new insights into the
pathogenesis of CHD, but their quantitative roles have not
been determined sufficiently to include them in risk predic-
tion equations. Moreover, accurate measurements of these
coagulation factors are not yet widely available to practicing
physicians.
In recent years there has been a growing interest in the
possibility that a condition called insulin resistance underlies
several metabolic risk factors, predisposing the individual to
premature CHD.116 Insulin resistance refers to a generalized
metabolic disorder in which various tissues are resistant to
normal levels of plasma insulin. Metabolic abnormalities
include defective glucose uptake by skeletal muscle, in-
creased release of free fatty acids by adipose tissue, overpro-
duction of glucose by the liver, and hypersecretion of insulin
by pancreatic b-cells. The presence of insulin resistance can
usually be detected clinically by truncal (or abdominal)
obesity117 and hyperinsulinemia.116 CHD risk factors often
present in patients with insulin resistance include the athero-
genic lipoprotein phenotype, hypertension, impaired glucose
tolerance, and a prothrombotic state.116 This clustering of
several metabolic risk factors in a single patient has been
termed the metabolic syndrome.93 The major Framingham
risk factors include some of the components of metabolic
syndrome but not all. Thus, the aggregate risk carried by
patients with insulin resistance may be underestimated by
Framingham scores.
The final risk predictor is serum homocysteine level.
Persons with the rare congenital disorder homocysteinuria
develop severe arterial disease118; this discovery gave rise to
the theory that high homocysteine levels may be a cause of
CHD. Furthermore, according to several studies,119–122 mod-
erately elevated serum levels of homocysteine in the general
population are positively associated with CHD occurrence. In
addition, patients with a genetic defect in an enzyme produc-
ing high homocysteine levels also appear to be at increased
risk for CHD.123,124 Whether measurement of plasma homo-
cysteine concentrations is clinically useful in risk stratifica-
tion is uncertain but worthy of further investigation.
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Future research on these additional risk factors, which are
not included among the Framingham scores, could provide
new insights into mechanisms of atherogenesis. Eventually
some of these other factors may be useful additions to risk
prediction equations. Even now they may deserve some
consideration in therapeutic decisions. Still, an important
question should be addressed first: what proportion of CHD
events in the general population can be explained by the
major risk factors already used in the Framingham risk
scores? Some pathological studies125,126 suggest that only
about half of the variation in size of atherosclerotic lesions
can be attributed to known risk factors. On the other hand,
when the concept of excess coronary risk is used, the major
risk factors seemingly account for most of the premature
CHD in the United States. Excess risk represents risk greater
than that present in the absence of any risk factors, eg, no
smoking or diabetes, total cholesterol ,160 mg/dL, and
blood pressure ,120/80 mm Hg. Follow-up data from
screenees of the Multiple Risk Factor Intervention Trial127
indicate that about 85% of excess risk for premature CHD can
be explained by the major risk factors. Framingham data are
generally in accord with this conclusion; persons with a
low-risk profile (ie, optimal blood pressure, total cholesterol
160 to 199 mg/dL, HDL cholesterol $45 mg/dL for men or
$55 mg/dL for women, nonsmoking, nondiabetic) are at
quite low absolute risk for CHD.6 Although risk rises with
aging even in the absence of these major risk factors, absolute
risk remains relatively low, even in older people. Persons
with a low-risk profile generally have less than half the risk
of the average Framingham participant throughout life. Note
that the low-risk profile includes a total cholesterol level in
the range of 160 to 199 mg/dL. When the cholesterol level is
below 160 mg/dL, risk is markedly attenuated.
The mechanisms whereby various risk factors enhance risk
for CHD constitute a topic of growing interest. According to
recent concepts, coronary atherogenesis can be divided into 2
broad phases. The first is coronary plaque development
leading to stable, fibrotic lesions. When arterial narrowing by
obstructive lesions becomes sufficiently severe, coronary
blood flow can be impeded, producing stable angina pectoris.
The second phase of atherogenesis is formation of unstable
plaques; such plaques are prone to rupture or erosion, which
activates the clotting cascade. The result of plaque rupture is
an acute thrombotic event: unstable angina or acute myocar-
dial infarction.128,129 According to the Pathobiological Deter-
minants of Atherosclerosis in Youth (PDAY) study,125,126 each
of the major risk factors enhances development of fibrotic
plaques. Other lines of evidence point to cigarette smoking
and high blood cholesterol levels as important causes of
unstable plaques; the most convincing evidence of the role of
these 2 factors in producing plaque instability is the marked
reduction in acute coronary events (acute myocardial infarc-
tion and unstable angina) that follows smoking cessation130
and cholesterol-lowering therapy131–133 in patients with ad-
vanced atherosclerotic disease. Hypertension possibly pro-
motes enlargement of plaques more than it destabilizes
coronary lesions as suggested by the observation that blood
pressure lowering does not reduce the occurrence of acute
coronary events as much as smoking cessation and serum
cholesterol reduction.134,135 Nonetheless, Framingham data6
demonstrate that sustained hypertension carries as much
long-term risk for myocardial infarction as do smoking and
elevated cholesterol. There is no doubt that high blood
pressure accelerates atherogenesis125,126 and lowering of blood
pressure reduces CHD risk.136,137 Thus, blood pressure control
is a necessary element in long-term prevention of CHD. The
specific role played by diabetes mellitus in plaque growth and
rupture remains unclear. Recent autopsy data suggest that
hyperglycemia promotes plaque development138; the high
incidence of myocardial infarction in patients with diabetes
raises the possibility that hyperglycemia also predisposes
such patients to plaque rupture or erosion.139 Framingham
data cannot delineate the influence of risk factors in the
different stages of atherogenesis; instead, they provide a
summation of effects. In most Framingham reports, the
coronary end points on which risk scores are based include
summation of onset of angina pectoris, acute myocardial
infarction, coronary insufficiency, and coronary death. In the
accompanying report,6 another end point, hard CHD, is
added; this end point excludes angina pectoris and may more
closely reflect the incidence of thrombotic coronary events.
Relative Versus Absolute Risk
Relative risk is the ratio of the likelihood of CHD developing
in persons with and without a given risk factor or at a given
intensity of a risk factor. Absolute risk is the probability of
developing CHD in a finite period, eg, within the next 10
years. In a sense, relative risk reflects the rate at which a
person is accruing absolute risk. Serum cholesterol data
provide a good example of the difference between relative
and absolute risk. A young adult with a high serum choles-
terol level carries a low absolute risk for CHD but has a high
relative risk compared with a young adult with a low serum
cholesterol level. The hypercholesterolemic young adult is
unlikely to develop CHD in the next 10 years, but his or her
chances of experiencing premature CHD in the long term (eg,
before age 65) are high. Long-term follow-up data from
Framingham confirm this concept: cholesterol levels mea-
sured in young adulthood are inversely associated with life
expectancy.47 Results from other studies140–142 further support
the concept that a high relative risk in young adulthood is
transformed into a high absolute risk in the long run. The goal
for reducing elevated serum cholesterol in young adults thus
is to retard atherogenesis throughout life, not to prevent
myocardial infarction in the next decade. This essential aim
does not necessarily justify the use of cholesterol-lowering
drugs that are expensive and of uncertain long-term safety in
young adulthood; however, it does warrant attempts to
modify lifestyle habits and control other risk factors early in
adulthood to slow atherogenesis. This aim also justifies
efforts to detect elevated serum cholesterol in young adults.143
There is a current misconception on the part of some
investigators that absolute risk for CHD can be almost fully
reversed by aggressive cholesterol-lowering therapy initiated
after atherosclerosis has become advanced.144,145 Certainly
reduction of serum cholesterol levels in patients with ad-
vanced atherosclerotic disease does substantially reduce mor-
bidity and mortality from CHD,131–133 but the persistently high
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rate of coronary events even in those patients who receive
cholesterol-lowering drugs reveals that risk cannot be fully
reversed.
Framingham risk scores furnish 2 ways to estimate relative
risk. One compares a given individual’s estimated risk with
the absolute risk of an individual at low risk, ie, a person who
is largely without risk factors. The other compares a given
individual’s estimated risk with the risk of an average person
of the same age and sex. The latter ratio is commonly used,
although it tends to underestimate the preventable component
of coronary risk because the average American is developing
coronary atherosclerosis at an unnecessarily rapid rate. A
better way to assess the full potential for risk reduction, when
introduced relatively early in life, is to compare estimated
absolute risk with truly low risk. As indicated before, about
85% of excess risk for CHD in the whole US population can
be explained by the sum of major risk factors.127 Total excess
risk for an individual patient can be estimated by subtracting
that person’s absolute risk from the absolute risk of a person
of the same age and sex who is at low risk.
Estimated absolute risk should provide a guide to intensity
of risk factor management. For example, the NCEP2,3 places
increased emphasis on the absolute-risk calculation to guide
considerations on when to use cholesterol-lowering drugs.
Treatment of other risk factors is mandated to prevent other
complications besides CHD (eg, blood pressure control to
prevent stroke and smoking cessation to prevent lung cancer
and other pulmonary diseases); effective therapies therefore
cannot be delayed. In contrast, cholesterol management aims
primarily to prevent CHD; consequently, aggressive choles-
terol lowering through the use of powerful drugs is best
reserved for persons at high absolute risk.2,3 Recent clinical
trials131–133 have demonstrated the efficacy and safety of
cholesterol-lowering drugs for prevention of CHD in patients
at high absolute risk; sufficient information to prove the
long-term safety of cholesterol-lowering drugs is not avail-
able to justify their use in patients at moderate risk.
Primary Versus Secondary Prevention
Primary prevention generally means the effort to modify risk
factors or prevent their development with the aim of delaying
or preventing new-onset CHD. The term “secondary preven-
tion” denotes therapy to reduce recurrent CHD events and
decrease coronary mortality in patients with established
CHD. Secondary prevention strategy is aimed at both control
of risk factors and direct therapeutic protection of coronary
arteries from plaque eruption. This dual approach has led
some investigators to view secondary prevention efforts as
treatment of coronary artery disease. Although there may be
a slim distinction between secondary prevention and high-
risk primary prevention, once a patient has exhibited clinical
atherosclerotic disease, he or she is unequivocally at very
high risk for developing new acute coronary events.2,3 Ag-
gressive preventive measures are thus justified. For purposes
of secondary prevention, manifest atherosclerotic disease
includes angina pectoris or a history of documented myocar-
dial infarction, history of coronary artery procedures (bypass
graft or angioplasty), peripheral artery disease, aortic aneu-
rysm, and symptomatic coronary artery disease.2,3 The AHA
has published recommendations for risk management in
patients with established atherosclerotic disease.146
Framingham risk scores in the accompanying publication6
apply essentially to primary prevention. These scores were
obtained in patients without manifest atherosclerotic disease.
Risk factors continue to affect outcomes in patients with
manifest atherosclerotic disease, but absolute risk predictions
based on the current presentation6 do not apply to patients
with established atherosclerotic disease.
Potential Uses of Framingham Risk Charts
The Framingham charts provide a realistic picture of a given
individual’s true absolute and relative risks. Therefore, they
can be helpful in tailoring a plan for risk factor management.
The NCEP2,3 used Framingham data to link recommended
intensity of cholesterol management to absolute risk. NCEP
risk categories,2,3 however, were more broadly outlined. The
new Framingham scores aim to provide a more precise
delineation of absolute risk, which in turn might lead to a
more precise selection of appropriate therapy. For example,
the new scores might be used in deciding when to initiate
drug therapy for risk reduction.
Another potential use of the Framingham charts is patient
education and motivation. Patients with low risk scores can
be reassured. Those with higher scores should, as a minimum,
be counseled to adopt risk-reducing life habits, ie, smoking
cessation, dietary change, weight control, and exercise. For
the patient, risk scores highlight the cumulative danger of
having several risk factors. It must be emphasized, however,
that a low absolute risk, particularly in young adults, does not
ensure a lifetime of low risk.143 Not only does absolute risk
increase with aging, but the number and severity of metabolic
risk factors typically worsen with aging. Serum cholesterol
levels rise throughout young adulthood and into middle age.
In many people, systolic and diastolic blood pressures rise
progressively throughout adulthood, even into older age.
Insulin resistance usually worsens with aging, resulting in a
progressive increase in the prevalence of noninsulin-depen-
dent diabetes mellitus. All of these changes with aging are
accentuated in persons who gain weight and become more
sedentary with the passing years. Thus, both the NCEP2,3 and
the Joint National Committee4,5 recommend periodic retesting
for risk factors, even for persons previously found to be at
low risk. Total cholesterol and HDL cholesterol should be
checked at least once every 5 years and blood pressure
measured at least once every 2 years.
The risk charts add perspective by comparing the relative
importance of the different risk factors. For example, the
charts indicate that high total cholesterol and low HDL-cho-
lesterol levels carry an absolute risk similar to those imparted
by smoking, diabetes, and moderate hypertension. These
similar influences of different factors on CHD risk are not
widely appreciated. It is critical to point out, however, that
risk scores presented in the charts are not accurate when risk
factors are present in severe form; thus, heavy smoking,
marked hypertension, and extremely elevated serum choles-
terol confer much greater risk than that suggested by the
scores. Furthermore, when young adults manifest severe
forms of risk factors, the danger of developing premature
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CHD is especially high. For such patients, a major effort
should be made to modify risk factors.
Age as a Risk Factor
Absolute risk for CHD increases with age in both men and
women71–75 as the result of progressive accumulation of
coronary atherosclerosis with aging. In fact, most new-onset
CHD now occurs after age 65; this trend is especially
pronounced in women.147 Because of a high absolute risk in
elderly patients, opportunities for primary prevention in this
age group should be substantial. The extent to which preven-
tion can be realized in older persons remains somewhat
uncertain, however, because of a lack of clinical trials that
specifically target this age group. Most investigators2–5 agree
that primary prevention efforts are justified in the “young”
elderly, ie, those aged 65 to 75 years. Framingham data afford
absolute risk estimates for people in this age range that may
assist in selection of candidates for aggressive primary
prevention. A growing consensus moreover extends second-
ary prevention efforts to the “old” elderly, ie, .75 years.2–5
Primary prevention efforts in older elderly people should be
addressed more cautiously but cannot be ruled out. Certainly
smoking cessation at any age is prudent. Treatment of systolic
hypertension even in very old patients reduces risk for both
stroke and CHD.148 On the other hand, initiation of choles-
terol-lowering therapy in persons aged .75 years for the
purpose of primary prevention is an issue of some dispute;
nonetheless, if therapy was started in the earlier years, it
should be continued.
Cigarette Smoking
Cigarette smoking is a powerful risk factor that probably
predisposes the smoker to CHD in several ways. According to
autopsy studies,126,127,149,150 smoking accelerates coronary
plaque development. Framingham data further reveal that
smoking is a powerful risk factor for myocardial infarction,
even stronger than for angina pectoris.13 Of great importance
is the fact that smoking cessation rapidly and markedly
reduces risk for myocardial infarction.130 These 2 findings
taken together imply that cigarette smoking probably desta-
bilizes coronary plaques and promotes plaque rupture and
coronary thrombosis. Thus, smoking is especially dangerous
in patients with advanced coronary atherosclerosis.
The Framingham scores assign 2 risk points for cigarette
smoking. This seems appropriate for patients who smoke
about 1 package of cigarettes a day. Those who smoke more
are at extremely high risk for premature CHD, much more so
than revealed by the risk score. Moreover, the dangers of
cigarette smoking to overall health go beyond its effects on
risk for CHD. Smoking is the predominant cause of periph-
eral arterial disease,151 it is a major risk factor for stroke,18 it
underlies many different forms of cancer, and it causes
chronic lung disease. For these reasons, cigarette smoking is
the foremost preventable cause of death in the United
States152; efforts toward smoking cessation deserve high
priority in any prevention strategy.
Hypertension
High blood pressure is a potent risk factor. The Framingham
risk chart highlights the danger imparted by moderate hyper-
tension.6 Moderate elevations of blood pressure are a partic-
ularly strong risk factor in women. Unfortunately, a substan-
tial portion of the US population with hypertension is
inadequately treated.153 The Joint National Committee re-
ports4,5 recommend therapy for blood pressure readings con-
sistently .140/90 mm Hg. The Joint National Committee4
encourages modification of lifestyle to reduce blood pressure
but also recognizes that medications are often required to
achieve normalization of blood pressure. In previous Joint
National Committee reports,4 absolute risk for CHD was not
considered in setting target values for blood pressure lower-
ing because of the other dangers accompanying untreated,
moderate hypertension (eg, stroke and renal failure). The
normal range for blood pressure (,140/90 mm Hg) thus
becomes the target for all persons. Ample clinical trial
evidence134 indicates that many strokes can be prevented by
blood pressure control. Certainly another purpose of hyper-
tension management is reduction of CHD risk; recent data
from clinical trials indicate that blood pressure lowering does
in fact decrease CHD risk.136,137 The most recent Joint Na-
tional Committee report5 recommends different therapeutic
regimens, depending on blood pressure range, presence of
major risk factors, and evidence of target organ damage or
clinical cardiovascular disease. When diabetes is present, risk
status is elevated to that associated with target organ damage
or clinical cardiovascular disease. For patients at moderate
risk, as defined by both blood pressure and other risk
correlates, changes in life habits are the recommended ther-
apy; for patients at high risk, antihypertensive drugs are
required.
The NCEP2,3 gives equal weight to untreated and treated
hypertension in assessment of risk; both count as 1 risk factor
in the NCEP guidelines. The Framingham scores chart
hypertension according to degree of severity and use current
blood pressure for assessment whether or not specific therapy
is being used. This approach is in accord with the way blood
pressure data are collected at Framingham and may offer an
improved estimation of risk. In clinical practice, of course,
several blood pressure measurements are preferable to single
readings when deciding on type and intensity of treatment.4,5
Serum Cholesterol
Serum total cholesterol levels correlate with CHD risk over a
broad range of levels. Although the NCEP2 defines a total
cholesterol level ,200 mg/dL as desirable, CHD risk is lower
still at levels ,160 mg/dL; thus, in the Framingham chart,6
total cholesterol levels ,160 mg/dL are scored with 23
points for men and 22 points for women. Total cholesterol
levels between 160 and 199 mg/dL are scored as 0; values of
200 to 239 mg/dL, called “borderline-high” for both men and
women,2,3 receive 1 point. Total cholesterol of 240 to 279
mg/dL is scored as 2 points for both men and women; $280
mg/dL, as 3 points for both men and women.
The NCEP2,3 identifies serum LDL cholesterol, not total
cholesterol, as the primary target of cholesterol-lowering
therapy. An approximate correspondence between total cho-
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lesterol and LDL cholesterol, as developed by the NCEP,2,3 is
shown in the Table. In deference to the NCEP, Framingham
investigators have also provided risk scores based on LDL-
cholesterol levels. It should be noted, however, that the
Framingham database for total cholesterol is greater than
LDL cholesterol, and Framingham scores accompanying
different levels of total and LDL cholesterol do not correlate
in precisely the same manner as that of the Table. For
example, in men, the Framingham scores do not show a
gradient of risk between desirable LDL cholesterol (100 to
129 mg/dL) and borderline-high risk LDL cholesterol (130 to
159 mg/dL) as noted for corresponding values for total
cholesterol. Moreover, risk scores in men are lower for higher
corresponding levels of LDL cholesterol than for total cho-
lesterol. A similar inconsistency is noted for women. Other
data sets that include greater numbers of patients than the
Framingham study reveal a more continuous relationship
between serum cholesterol risk and incidence of CHD.127
Thus, when using Framingham cholesterol data for risk
stratification, it may be preferable to use total cholesterol over
LDL cholesterol because of the greater strength of the data
set. Alternatively, risk scores for LDL cholesterol could be
adjusted to those for total cholesterol using the corresponding
values shown in the Table.
According to the NCEP guidelines,2,3 total cholesterol
levels can be used in initial detection of high serum choles-
terol; however, serum LDL-cholesterol values should be used
in risk assessment and evaluation of response to therapy. For
long-term monitoring of most patients on therapy, the serum
total cholesterol value will suffice. For individual patients
with a high total cholesterol level based on high serum HDL
cholesterol, total cholesterol will overestimate risk. This
misclassification of risk occurs more often in women than
men because women tend to have high HDL concentrations.
The NCEP2,3 recommends estimation of serum LDL choles-
terol in any patient whose total cholesterol is $240 mg/dL or
200 to 239 mg/dL in the presence of 2 or more CHD risk
factors.
Framingham scores for total cholesterol (and LDL choles-
terol) underestimate risk in patients with severely high
cholesterol levels, eg, those with familial hypercholesterol-
emia,154 or in some other genetic forms of hyperlipidemia.2,3
The NCEP2,3 provides guidelines for treatment of these
patients. The NCEP further recommends that young adults
with moderate hypercholesterolemia (LDL cholesterol 160 to
219 mg/dL) should not receive cholesterol-lowering drugs
when they have no other risk factors. This recommendation is
justified by the Framingham risk scores; projected 10-year
risks in young adults with LDL-cholesterol levels in this
range are low. Nonetheless, because of a high relative risk
accompanying high-risk LDL-cholesterol levels, efforts to
safely and inexpensively reduce cholesterol levels with non-
drug therapy should be used to slow the development of
coronary atherosclerosis in young adults. According to the
NCEP,2,3 most young adults with still higher LDL-cholesterol
levels ($220 mg/dL) generally deserve drug therapy to retard
atherogenesis.
Middle-aged men (aged 45 to 65 years) with high serum
cholesterol levels (.240 mg/dL; LDL-cholesterol levels
.160 mg/dL) carry an increased risk for CHD. The NCEP2,3
recommends that physicians counsel such patients on diet
modification, weight control, and increased physical activity.
An important question is when to initiate cholesterol-lower-
ing drugs in middle-aged men. According to the NCEP
guidelines, cholesterol-lowering drugs can be considered for
middle-aged men with LDL-cholesterol levels .190 mg/dL
or $160 mg/dL in the presence of $2 CHD risk factors. The
recent West of Scotland Coronary Prevention Study
(WOSCOPS)132 confirms that cholesterol-lowering drugs will
safely and effectively reduce CHD rates in middle-aged men
at high risk. A critical question is whether Framingham risk
scores provide incremental assistance in selection of patients
for initiation of drug therapy beyond the cut points proposed
in the NCEP guidelines.3 At present it is not possible to define
a precise increment of risk above the Framingham average
risk that justifies starting a cholesterol-lowering drug. The
average 10-year risk for older age groups looks relatively
high, even higher than that of the placebo group of
WOSCOPS132; however, it must be noted that Framingham
scores use “softer” CHD end points, including new-onset
angina pectoris, whereas the WOSCOPS trial included only
“harder” CHD end points. The inclusion of hard CHD in
Framingham scores helps redress the balance somewhat.
According to the NCEP,2,3 if a middle-aged man has an
LDL-cholesterol level $160 mg/dL and 2 other major CHD
risk factors, the use of cholesterol-lowering drugs should be
considered. Using the Framingham scores,6 this combination
of risk factors produces a threefold increase in risk for CHD
compared with the patient at low risk. In other words,
cholesterol-lowering drug therapy probably should be con-
sidered for a middle-aged man with a high-risk LDL-choles-
terol level and 3 times the absolute baseline risk. Framingham
data thus appear to be consistent with current NCEP guide-
lines. However, a word of caution must be added about using
absolute Framingham risk scores as a trigger for starting
cholesterol-lowering drug therapy. The decision-making pro-
cess for cholesterol-lowering drugs must be viewed as
“shooting at a moving target.” Absolute risk scores may be
dramatically altered by institution of other risk-reducing
efforts. For example, the increment in risk accompanying
cigarette smoking can be erased in 2 to 3 years by smoking
cessation. In addition, blood pressure reduction in a hyper-
tensive patient may significantly decrease risk for CHD.
Finally, in the Physicians’ Health Study,155 it was reported
that risk for acute coronary events can be markedly decreased
by the use of low-dose aspirin; many middle-aged men ingest
aspirin on a regular basis. Therefore, starting a cholesterol-
Comparable Levels for Serum Total Cholesterol and
LDL Cholesterol
Total Cholesterol LDL Cholesterol
Level Category Level Category
,200 mg/dL Desirable ,130 mg/dL Desirable
200–239 mg/dL Borderline high 130–159 mg/dL Borderline high
$240 mg/dL High $160 mg/dL High
LDL indicates low-density lipoprotein.
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lowering drug should not become a therapeutic reflex when a
patient crosses a certain risk threshold. A patient’s absolute
risk must be reassessed in light of other therapeutic strategies
being used simultaneously. In addition, the benefits of max-
imum nondrug therapy (dietary change, weight reduction,
increased physical activity) should be added to the risk
equation before starting cholesterol-lowering drugs in mid-
dle-aged men with moderately elevated serum cholesterol
levels.
Benefit from the use of cholesterol-lowering drugs for
primary prevention in elderly men (.65 years) with high
cholesterol levels remains to be demonstrated through clinical
trials. Framingham risk scores warn that risk increases pro-
gressively with aging. The chart further notes that risk in the
elderly is further increased by high cholesterol levels. The
total number of older men in the United States with relatively
high cholesterol levels is large and growing, and the potential
for reducing CHD rates in older men with cholesterol-
lowering drugs may therefore be considerable. However, the
lack of specific clinical trials that document the degree of
benefit from drug therapy leads some authorities to urge
caution when resorting to cholesterol-reducing agents for
primary prevention in elderly men. The same note of caution
mentioned for use of cholesterol-lowering drugs in middle-
aged men is needed for elderly men. Without question, use of
drugs in older patients should be individualized. In contrast,
for secondary prevention in older men, a more aggressive
approach, in which drugs are used when needed to reach
target LDL goals, can be recommended.
A substantial proportion of postmenopausal women have
elevated cholesterol levels.3 However, according to Framing-
ham scores, their 10-year risk for CHD is considerably lower
than that for men. The difference between men and women is
particularly pronounced for hard CHD end points. In other
words, the diagnosis of angina in women contributes a sizable
fraction of all CHD end points in the Framingham cohort. The
virtual lack of rise in risk for total CHD after age 55 in
women is misleading, as shown by the progressive rise in risk
for women with hard CHD. These findings are consistent
with population studies that show most CHD morbidity and
mortality in women occurs after age 70.147 Regardless, the
lower absolute risk in women compared with men up to age
75 alludes to the need for more caution when considering
aggressive cholesterol-lowering therapy for primary preven-
tion in postmenopausal women. Framingham data, however,
do not speak against the use of cholesterol-lowering drugs in
postmenopausal women with severe hypercholesterolemia or
those with moderately high cholesterol levels combined with
a high score from other risk factors.
Low HDL Cholesterol
The Framingham Heart Study has been a strong proponent of
the concept that a low serum HDL-cholesterol level is a major
risk factor for CHD.51–57 Framingham reports advise that the
inverse association between HDL-cholesterol levels and
CHD risk at least equals the positive association between
CHD risk and serum LDL-cholesterol levels. Data from
Framingham were influential in the NCEP decision to clas-
sify a low HDL level as a major risk factor for CHD.2,3
Despite a strong epidemiological association, the mechanisms
underlying the HDL-CHD link remain poorly understood.
Some researchers propose that HDL attenuates the atheroge-
nicity of LDL; if so, a low HDL level may directly promote
atherogenesis. Results of the PDAY study125,126 as well as
some animal research156,157 are consistent with this concept.
On the other hand, a low HDL level often signifies the
presence of an excess of atherogenic lipoproteins (very
low-density lipoprotein [VLDL] remnants and small LDL
particles) that typically are not measured158; these too may
independently raise risk in persons with a low HDL level. In
addition, a low HDL concentration commonly coexists with
an insulin-resistance state,159 which may be another unmea-
sured risk factor. These multiple associations possibly explain
why a low serum HDL-cholesterol concentration emerges as
such a powerful risk factor158; not only may it directly
promote atherogenesis, but it is a marker for other risk
factors.
The inverse relationship between HDL level and CHD risk
extends over a broad range of HDL levels. The NCEP2,3
defines 3 categories of HDL cholesterol: low (,35 mg/dL),
normal (35 to 60 mg/dL), and high (.60 mg/dL). The NCEP
classifies low HDL cholesterol as a major risk factor; con-
versely, a high level is called a “negative” (protective) factor.
Framingham scoring creates 5 categories of HDL cholesterol
consistent with the finding of a continuous relationship
between levels and risk. In accord with the NCEP,2,3 negative
scores are assigned to HDL-cholesterol levels $60 mg/dL.
On the basis of the score, low HDL-cholesterol levels appear
to impart a greater risk for CHD in women compared with
men6; this appearance is misleading, however, because each
point carries more absolute risk in men.
The potential uses of HDL measurements are threefold:
risk assessment, adjusting intensity of LDL-cholesterol–low-
ering therapy, and direct target of therapy. Specific therapies
to raise HDL concentrations are not highly effective or
practical. Evidence from clinical trials that documents benefit
from specific HDL-raising therapies is thus lacking. Certainly
smoking cessation, weight control, and regular exercise
should be encouraged because of their tendency to raise HDL
levels and, importantly, because they have beneficial effects
on other risk factors. Nicotinic acid is an effective HDL-
raising agent,160,161 but unfortunately it is not well tolerated by
many patients. Thus, at present the principal usefulness of
HDL-cholesterol measurement is for risk assessment and
guidance on intensity of management of other risk factors,
especially elevated serum LDL cholesterol.
Diabetes Mellitus
Patients with diabetes mellitus carry an increased risk for
CHD. Framingham data suggest that hyperglycemia as such
is an independent risk factor.58–70 The mechanisms for this
effect are not well understood. Whether improved control of
hyperglycemia in diabetic patients reduces risk for CHD
remains uncertain. Nonetheless, improved glycemic control
apparently does reduce the microvascular complications of
diabetes162; control of hyperglycemia is thus indicated regard-
less of its effects on macrovascular disease, ie, atherosclerotic
disease. In addition to the independent risk factor hypergly-
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cemia, patients with diabetes commonly have other risk
factors (eg, hypertension, low serum HDL cholesterol, and
hypertriglyceridemia); these additional risk factors accentuate
the danger of CHD developing in many diabetic patients.163
To make matters worse, once a patient with diabetes develops
clinical CHD, cardiac complications occur with increased
frequency164; diabetic patients with CHD experience more
morbidity and mortality than do nondiabetic patients with
CHD. Control of other risk factors to reduce the likelihood of
initially developing CHD consequently becomes a critical
need for diabetic patients. Recent clinical trials131–133 docu-
ment a significant reduction in recurrent coronary events
accompanying cholesterol-lowering therapy in diabetic pa-
tients with established CHD. This result demonstrates the
efficacy of control of other risk factors in patients with
diabetes.
Role of Risk Factors in Women
Prediction scores illustrate the marked difference in CHD risk
between men and women before age 70. Onset of CHD in
women lags behind that in men by 10 to 15 years. Nonethe-
less, the data clearly document that the major risk factors
have a substantial impact on absolute CHD risk in women.
For the US population as a whole, as many women as men
eventually die of CHD.147 Therefore, risk factors in women
cannot be ignored. Cigarette smoking should be strongly
discouraged. Hypertension requires effective therapy. Matu-
rity-onset diabetes mellitus should be delayed or prevented if
possible by weight control and regular exercise. On the other
hand, moderately elevated LDL-cholesterol levels in women
need not be treated as aggressively in primary prevention as
is necessary in men, partly because of overall lower risk and
normally higher HDL-cholesterol levels in women.
Clustering of Risk Factors
The Framingham charts clearly show the additive nature of
risk factors. There is growing recognition that many persons
suffer from multiple risk factors. The tendency of risk factors
to cluster in a single individual is being increasingly recog-
nized.165,166 Obesity and physical inactivity contribute impor-
tantly to the development of multiple risk factors in the
American population; this clustering of multiple metabolic
risk factors is called the metabolic syndrome.93 The increased
risk associated with this syndrome is reflected by the Fram-
ingham scores for HDL cholesterol, blood pressure, and, in
some persons, diabetes mellitus. Risk will be further accen-
tuated in smokers with several metabolic risk factors. There is
an increasing need to identify persons with multiple risk
factors and, because of their high risk, to initiate management
directed at all risk factors.
Limitations of the Framingham Risk Scores
Participants in the Framingham Heart Study are not neces-
sarily representative of the total US population. Various
geographic and ethnic groups are underrepresented. The
impact of specific risk factors may vary in different popula-
tions. Even so, many separate studies document that the
major risk factors investigated in the Framingham cohort hold
up as risk factors in other populations.167–175 Although poten-
tial differences among various populations must be kept in
mind when applying the Framingham scores, quantitative
differences in risk predictions are likely to be small among
most populations.
Another limitation of Framingham risk scoring is that it
does not take into account all risk factors for CHD. Not
included are triglycerides, small LDL particles, Lp(a), coag-
ulation factors, and homocysteine. All of these risk factors
may not be totally independent of the major risk factors, and
the measurements of some are not readily available in clinical
practice. Their quantitative impact on CHD risk is not as well
defined as for the major risk factors; hence, assigning specific
scores is difficult. Nonetheless, each of these factors probably
makes some independent contribution to CHD risk, and in the
future, risk assessment may be improved by incorporating
them into predictive equations.
Conclusions
New Framingham risk scores constitute a step toward inte-
grating Framingham data into national recommendations for
blood pressure and cholesterol control. A new classification
of risk factor intensity in these latest Framingham scores is
largely in accord with classifications developed by the Joint
National Committee and the NCEP. Framingham categories
for blood pressure are similar to those used by the Joint
National Committee.4,5 For total and HDL cholesterol levels,
Framingham charts subcategorize various cholesterol levels
to a greater extent than the NCEP,2,3 although a similar
scheme of cut points is used. The Framingham scores
particularly highlight the fact that aging progressively en-
hances risk. Moreover, the difference in CHD risk between
men and women up to the age of 70 to 74 years is striking.
The Framingham scores offer both general and specific
applications. They suggest priorities for instituting primary
prevention strategies and point to factors deserving increased
emphasis and those needing less attention. They provide
useful estimates of both relative and absolute risk associated
with the various risk factors. The authors of future revisions
of guidelines and recommendations for control of blood
pressure, cholesterol, diabetes, and smoking would do well to
pay close attention to the concepts contained in these updated
Framingham risk scores.
The revised charts should prove useful to healthcare
professionals managing risk factor reduction in individual
patients. Risk scores can both motivate and reassure. They
also may assist in selection of specific therapies. Of critical
importance is the fact that risk factors compound one another.
Treating hypertension or lowering serum cholesterol levels in
a diabetic patient reduces risk for future CHD just as
effectively as controlling hyperglycemia. The Framingham
scores admonish healthcare professionals to look at the whole
patient and to recognize the cumulative nature of risk factors.
A multifactorial approach to risk reduction offers the best
opportunity for (1) saving patients at high risk and (2)
preventing development of high-risk status in the first place.
Of special note, the Framingham data reveal the potential
for primary prevention of CHD. Recent dramatic results from
secondary prevention trials of cholesterol-lowering therapy
highlight the urgency of risk factor management in patients
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with established CHD. Nonetheless, if the burden of CHD in
American society is to be substantially reduced, primary
prevention must be improved. Framingham research points
the direction for these efforts. Risk factor modification in the
general public and persons at high risk offers the best
opportunity for effectively reducing the prevalence of CHD
in the United States.
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